Boehringer Ingelheim showcases its leading avian vaccines and services at WVPAC 2019

Bangkok, Thailand, Thursday, 12/09/2019 - 11:00

Boehringer Ingelheim continues to lead¹the hatchery vectored vaccine market worldwide with VAXXITEK^® and NEWXXITEK^®
Through its Vaccination Technologies and Services (VTS), the company continues to focus on innovation

Bangkok, Thailand, 12 September 2019 - Boehringer Ingelheim will exhibit at the 21^st World Veterinary Poultry Association Congress (WVPAC), one of the most important global poultry congresses, and present its solutions for hatchery vaccination.

Jérôme Baudon, Head of
Poultry Business Unit

“This year’s theme of the conference is ‘Poultry: the value of protein for one’s health’ focusing on food safety and biosecurity. Both fit very well with our aspiration to create the future of poultry well-being through preventive care. We look forward to engaging with experts and opinion leaders in productive conversations at the event,” shared Jérôme Baudon, Head of Poultry Business Unit, Boehringer Ingelheim.

Leading position in hatchery vaccination thanks to vector vaccines

VAXXITEK^® HVT+IBD, the HVT vector vaccine that protects against infectious bursal disease, celebrated a milestone of over 100 billion birds vaccinated last year.

NEWXXITEK^® HVT+ND, the HVT vector vaccine that protects against Newcastle disease without inducing any post-vaccination adverse reaction.

VAXXITEK^® HVT+IBD+ND, the latest poultry vaccine from Boehringer Ingelheim - the trusted leader¹ in IBD vector vaccine technology - has been approved² by the USDA authorities early August 2019.

A comprehensive solution for Infectious Bronchitis vaccination

The causative agent of IB is an avian coronavirus which is able to mutate and produce new viruses, called variants. The development and licensing of new vaccines each time a new variant appears is impractical, costly and time consuming. That is why Boehringer Ingelheim offers both Mass and Variant IB vaccine for a cross-serotype protection. Hatchpak^® Bioral H120 has been designed to offer a high number of doses per amp hatchery vaccination solution while Bioral H120 NeO and Gallivac IB88 NeO are available in innovative effervescent tablets for a simplified vaccination administration. Part of the protection includes the inactivated range with Gallimune and Cor-2 products.

Innovation in vaccination equipment with its Vaccination Technologies and Services

The Ovo-Jector developed by Boehringer Ingelheim is one of the most compact In-Ovo machine in the market with selective vaccination and transfer. It can selectively vaccinate up to 42,000 eggs per hour. VTS fits all hatcheries' needs designing sprayers and solutions for day-old chick injections.

“The Vaccination Technologies and Services has been identified as a strategic initiative for our poultry business and it is fully in line with our goal to provide best services to hatcheries. Vaccination equipment is an integral part of our value proposition,” said Chris Fritts, VTS Global Head, Boehringer Ingelheim.

Boehringer Ingelheim will be present at booth D4, concourse Bhiraj hall, 2^nd floor.

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost 4 billion euros in 2018 and presence in more than 150 markets.

Across the globe, our 10,000 employees create the future of animal wellbeing through their daily work. We believe in prevention over treatment and therefore, we focus on developing innovative solutions in the field of vaccines, parasiticides and therapeutics. With a large portfolio of advanced, preventive healthcare products, tools and services, we support our customers in taking care of the health of their animals.

For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: https://annualreport.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.